Author:
Xu Peng-Peng,Sun Yi-Feng,Fang Ying,Song Qi,Yan Zi-Xun,Chen Yi,Jiang Xu-Feng,Fei Xiao-Chun,Zhao Yan,Leboeuf Christophe,Li Biao,Wang Chao-Fu,Janin Anne,Wang Li,Zhao Wei-Li
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Lenz, G. & Staudt, L. M. Aggressive lymphomas. The New England journal of medicine 362, 1417–1429, doi:
10.1056/NEJMra0807082
(2010).
2. Zhou, Z. et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123, 837–842, doi:
10.1182/blood-2013-09-524108
(2014).
3. Sehn, L. H. & Gascoyne, R. D. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125, 22–32, doi:
10.1182/blood-2014-05-577189
(2015).
4. Leech, A. O., Cruz, R. G., Hill, A. D. & Hopkins, A. M. Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis. Annals of translational medicine 3, 184, doi:
10.3978/j.issn.2305-5839.2015.08.01
(2015).
5. Zhao, C. et al. Dysregulation of JAM-A plays an important role in human tumor progression. International journal of clinical and experimental pathology 7, 7242–7248 (2014).
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献